

POSTER PRESENTATION

Open Access

Transfusions in patients with leukaemia admitted to an intensive care unit

M Madsen*, L Russell, J Stensballe, J Bonde, A Perner

From ESICM LIVES 2015

Berlin, Germany. 3-7 October 2015

Intr

Mortality among leukemia patients admitted to the intensive care unit remains high [1] and bleeding complications are common in particular among thrombocytopenic patients [2]. Platelet levels measured in thrombocytopenic ICU patients reflect both the inherit and transfused platelets. ICU patients generally receive a high amount of transfusions [3] and hematological ICU patients are no exception.

Objectives

Our aim was to describe the number and type of transfusions given to patients with haematological malignancies admitted to an intensive care unit. Furthermore, we wanted to test if there was an association between the number of platelet transfusions given in the first three days after arrival at the ICU and 30 day-mortality.

Methods

This was a retrospective observational study with data from patients with ALL, AML and MDS admitted to the ICU at Rigshospitalet, Copenhagen University Hospital 2008-2012. Data were extracted from the electronic ICU patient charts, blood bank database and national registries. To test for an association between platelet transfusions and 30-day mortality, we used logistic regression adjusted by SAPS II.

Results

Our cohort included 112 patients. 104 (93 %) received at least one blood product with a median of 20 blood products (IQR 7.5-52.5). Eighty-five (76%) patients received one or more platelet transfusions (median 12, IQR 6-37). During the first three days in the ICU, 58 patients received at least one platelet transfusion (concentrate

Blood products given in the ICU to patients with leukaemia

Blood product	N	Lower Quartile	Median	Upper Quartile	Minimum	Maximum
Erythrocytes	101	4	8	14	1	51
Plasma	61	3	5	14	1	50
Platelets	85	6	12	37	1	119
All blood products	104	7.5	20	62.5	1	164

Figure 1

from 4 donors) (median 5, IQR 3-8). No association between the number of platelet transfusions given during the first three days in the ICU and 30-day mortality was observed (HR 1.004, 95%CI 0.895-1.126).

Conclusions

In this cohort of patients with haematological malignancies admitted to the intensive care unit the use of blood products was high. Platelet transfusion given in the first three days in the ICU was not associated with increased 30-day mortality.

Published: 1 October 2015

References

1. Cornell RF, Palmer J: **Adult acute leukemia.** *Dis Mon* 2012, **58**(4):219-38.
2. Drews RE: **Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.** *Clin Chest Med*.
3. Perner a, Smith SH, Carlsen S, Holst LB: **Red blood cell transfusion during septic shock in the ICU.** *Acta Anaesthesiol Scand* 2012, **56**(6):718-23.

doi:10.1186/2197-425X-3-S1-A248

Cite this article as: Madsen et al.: Transfusions in patients with leukaemia admitted to an intensive care unit. *Intensive Care Medicine Experimental* 2015 **3**(Suppl 1):A248.